230 related articles for article (PubMed ID: 33034815)
21. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
[TBL] [Abstract][Full Text] [Related]
22. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
23. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
24. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.
Ben-Shabat I; Hansson C; Sternby Eilard M; Cahlin C; Rizell M; Lindnér P; Mattsson J; Olofsson Bagge R
J Vis Exp; 2015 Jan; (95):52490. PubMed ID: 25650893
[TBL] [Abstract][Full Text] [Related]
25. Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence.
Vogel A; Ochsenreither S; Zager JS; Wacker F; Saborowski A
Cancer Treat Rev; 2023 Feb; 113():102501. PubMed ID: 36587472
[TBL] [Abstract][Full Text] [Related]
26. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion.
Uzgare RP; Sheets TP; Johnston DS
Anticancer Res; 2013 May; 33(5):1989-2000. PubMed ID: 23645748
[TBL] [Abstract][Full Text] [Related]
28. Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.
Dewald CLA; Warnke MM; Brüning R; Schneider MA; Wohlmuth P; Hinrichs JB; Saborowski A; Vogel A; Wacker FK
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008282
[TBL] [Abstract][Full Text] [Related]
29. Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study.
Kolb M; Forschner A; Artzner C; Grözinger G; Said I; Dittmann H; Seith F
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894309
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.
Carle X; Gastaud L; Salleron J; Tardy MP; Caujolle JP; Thyss A; Thariat J; Chevallier P
Bull Cancer; 2020 Dec; 107(12):1274-1283. PubMed ID: 33183739
[TBL] [Abstract][Full Text] [Related]
31. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
32. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
33. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department.
Öcal O; Eldem G; Karagoz AH; Kılıçkap S; Yalcin S; Balkanci F; Peynircioglu B
Cureus; 2021 Sep; 13(9):e17880. PubMed ID: 34660079
[TBL] [Abstract][Full Text] [Related]
34. Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment.
Heusner TA; Antoch G; Wittkowski-Sterczewski A; Ladd SC; Forsting M; Verhagen R; Scheulen M
Rofo; 2011 Dec; 183(12):1151-60. PubMed ID: 22033849
[TBL] [Abstract][Full Text] [Related]
35. [Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].
Kaprin AD; Ivanov SA; Unguryan VM; Kazantsev AN; Belov YV
Khirurgiia (Mosk); 2023; (7):94-99. PubMed ID: 37379411
[TBL] [Abstract][Full Text] [Related]
36. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.
Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T
AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562
[TBL] [Abstract][Full Text] [Related]
37. Heparin reversal with protamine sulfate after Percutaneous Hepatic Perfusion (PHP): is less more?
Facchetti N; Hinrichs JB; Becker LS; Schneider MA; Brüning R; Rademacher J; Lenz J; Kudrass K; Vogel A; Wacker FK; Dewald CLA
Cancer Imaging; 2023 Jul; 23(1):68. PubMed ID: 37452405
[TBL] [Abstract][Full Text] [Related]
38. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.
Forster MR; Rashid OM; Perez MC; Choi J; Chaudhry T; Zager JS
J Surg Oncol; 2014 Apr; 109(5):434-9. PubMed ID: 24249545
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion.
Ben-Shabat I; Belgrano V; Ny L; Nilsson J; Lindnér P; Olofsson Bagge R
Ann Surg Oncol; 2016 Apr; 23(4):1327-34. PubMed ID: 26628434
[TBL] [Abstract][Full Text] [Related]
40. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
